Rifaximin for prevention of recurrent hepatic encephalopathy
- First published 1 August 2012
- Aust Prescr 2012;35:169-71
- 1 October 2012
- DOI: 10.18773/austprescr.2012.076
Some of the views expressed in the following notes on newly approved products should be regarded as preliminary, as there may have been limited published data at the time of publication, and little experience in Australia of their safety or efficacy. However, the Editorial Executive Committee believes that comments made in good faith at an early stage may still be of value. Before new drugs are prescribed, the Committee believes it is important that more detailed information is obtained from the manufacturer's approved product information, a drug information centre or some other appropriate source.
Approved indication: prevention of recurrent hepatic encephalopathy
550 mg film-coated tablets
Australian Medicines Handbook section 5.1.10
Patients with chronic liver disease, such as cirrhosis, can develop hepatic encephalopathy. This is a neuropsychiatric syndrome with clinical features ranging from mild cognitive changes to confusion and coma. Hepatic encephalopathy may occur because the liver is unable to clear the ammonia which is produced by intestinal bacteria.
The treatment of hepatic encephalopathy aims to reduce the absorption of ammonia. Typically, lactulose is used as it is cathartic and reduces ammonia production by lowering the gut pH. Rifaximin is a semi-synthetic antibiotic which acts on the intestinal flora. It has been used in the treatment of hepatic encephalopathy,1 and has now been approved to prevent the recurrence of hepatic encephalopathy.
The tablets are taken twice a day. As the drug is minimally absorbed, most of the dose stays in the gut, but the systemic concentration increases as liver function decreases. There is minimal metabolism, with most of the drug being excreted unchanged in the faeces.
A double-blind trial of rifaximin in prevention involved 299 patients with cirrhosis who were in remission from recurrent hepatic encephalopathy. These patients were randomised to take rifaximin or a placebo for six months or until encephalopathy re-emerged. This occurred in 22.1% of the rifaximin group and 45.9% of the placebo group. Approximately four patients need to be treated for six months to prevent one episode of hepatic encephalopathy. Fewer patients (13.6% vs 22.6%) in the rifaximin group had hospitalisations involving hepatic encephalopathy. Nine patients need to be treated for six months to prevent one admission.2
During the trial the adverse events which occurred more frequently with rifaximin than with placebo included peripheral oedema, ascites, anaemia, arthralgia, fever and dizziness.2 Long-term treatment may lead to the development of resistant bacteria including Staphylococcus aureus. Some patients develop Clostridium difficile colitis.
The trial did not establish the efficacy of rifaximin as a stand-alone product as more than 90% of the patients were taking lactulose.2 A previous open-label trial in 140 patients suggested that lactulose alone prevents the recurrence of encephalopathy. After a median follow-up of 14 months, encephalopathy recurred in 19.6% of the lactulose group and 46.8% of the control group.3 It therefore seems appropriate that rifaximin is only approved for use when other treatments have failed or are contraindicated.
The Transparency Score is explained in New drugs: transparency, Vol 37 No 1, Aust Prescr 2014;37:27.